Tag: DESTINY-Lung04
DESTINY-Lung04 Delivers a First-Line PFS Advantage for Trastuzumab Deruxtecan in HER2-Mutant...
Results from a global Phase 3 trial demonstrated that trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) can delay disease progression longer than standard...
Pipeline Watch: August 2026 – Dealmaking Accelerates, a Pivotal Lung Cancer...
August 2026 was a busy month for the antibody-drug conjugate (ADC) field, with activity spanning the full arc of development. Highlights included early discovery partnerships, manufacturing alliances, a practice-changing phase 3 readout in lung cancer, and the first dosing of a novel Treg-depleting ADC.
